Search Result

Results for "

TNKS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (2) Apoptosis (6) Aurora Kinase (1) Bcr-Abl (2) c-Myc (1) CaMK (2) Caspase (1) CDK (3) Cyclin G-associated Kinase (GAK) (1) Deubiquitinase (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (2) FGFR (2) HIV (1) IRAK (1) Itk (1) LIM Kinase (LIMK) (2) LRRK2 (2) MAP4K (2) MAPKAPK2 (MK2) (1) MELK (1) p38 MAPK (1) PARP (41) PPAR (1) PROTACs (3) Reverse Transcriptase (1) Salt-inducible Kinase (SIK) (2) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (13) STAT (3) TNK1 (11) Tyrosinase (3) ULK (3) Wee1 (1) Wnt (8) β-catenin (6)
By Research Areas:	Cancer (51) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (5) siRNAs (13)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Recombinant Proteins

Antibodies

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15147

XAV-939 Maximum Cited Publications 190 Publications Verification	β-catenin PARP	Cancer
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC₅₀ values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .

HY-147245

Basroparib STP1002	PARP	Cancer
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC₅₀ of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC₅₀ of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .

HY-12418

Stenoparib 2 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent PARP1 and PARP2 inhibitor and also inhibits *TNKS1* and *TNKS2, with IC₅₀s of 2.0, 1.0, ～50 and ～50 nM for PARP1, PARP2, TNKS1 and TNKS*2, respectively, using ³²P-NAD ⁺ as substrate.

HY-13968

JW 55 5 Publications Verification	PARP	Cancer
JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC₅₀s of 1.9 μM and 830 nM respectively.

HY-12438

G007-LK 5+ Cited Publications	PARP	Cancer
G007-LK is a potent and selective inhibitor of *TNKS1* and *TNKS2, with IC₅₀*s of 46 nM and 25 nM, respectively.

HY-16910

WIKI4 4 Publications Verification	PARP β-catenin Wnt	Cancer
WIKI4 is a potent tankyrase inhibitor with an IC₅₀ of 26 nM for *TNKS2. WIKI4 potently inhibits Wnt/β-catenin* signaling and that its half-maximal response dose is 75 nM. WIKI4 mediates its effects on Wnt/β-catenin signaling by inhibiting the enzymatic activity of *TNKS2* . WIKI4 is cytotoxic to SCLC cells with an IC₅₀ value of 0.02 μM .

HY-14443

XMD8-92 10+ Cited Publications	Epigenetic Reader Domain ERK TNK1 CaMK	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity .

HY-13990

*NVP-TNKS656* TNKS656	PARP Apoptosis	Cancer
NVP-TNKS656 is a highly potent, selective, and orally active *TNKS2* inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

HY-123851

MSC2504877 M2912	PARP	Cancer
MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC₅₀s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .

HY-12975

AZ6102 3 Publications Verification	PARP	Cancer
AZ6102 is a potent dual *TNKS1* and *TNKS2* inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-147316

TP-5801	STAT TNK1	Cancer
TP-5801 is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-164478

G-631	PARP Wnt β-catenin	Cancer
G-631 is an orally active *tankyrase(TNKS1/TNKS2*) inhibitor. G-631 stabilizes AXIN and inhibits the Wnt/β-catenin signaling pathway. G-631 can be used in studies related to cancers such as colorectal cancer .

HY-19351

MN-64 3 Publications Verification	PARP	Cancer
MN-64 is a potent tankyrase 1 inhibitor, with IC₅₀s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for *TNKS1, TNKS*2, ARTD1 and ARTD2, respectively.

HY-U00422

K-756 2 Publications Verification	PARP	Cancer
K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of *TNKS1* and *TNKS2* with IC₅₀s of 31 and 36 nM, respectively.

HY-108845

Tenecteplase TNK-tPA	Ser/Thr Protease	Cardiovascular Disease
Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke .

HY-15811

XMD8-87 ACK1-B19	Tyrosinase	Cancer
XMD8-87 is a potent *TNK2* inhibitor with IC₅₀ values of 38 and 113 nM for the D163E and R806Q mutations, respectively.

HY-101243

XMD16-5	Tyrosinase	Cancer
XMD16-5 is a potent *TNK2* inhibitor with IC₅₀ values of 16 and 77 nM for the D163E and R806Q mutations, respectively.

HY-153996

CT1113	Deubiquitinase Apoptosis Bcr-Abl STAT c-Myc	Cancer
CT1113 is a selective, orally active USP25/USP28 inhibitor. CT1113 inhibits cancer cell proliferation, induces apoptosis, and causes G2/S phase cell cycle arrest. CT1113 reduces the levels of total BCR-ABL1, phosphorylated BCR-ABL1, total STAT5, and phosphorylated STAT5, but does not alter the mRNA level of BCR-ABL1. CT1113 is applicable to research related to pancreatic cancer, colon cancer, and acute leukemia .

HY-15800A

CZC-25146	TNK1 LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases .

HY-148061

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Cancer
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .

HY-126248

Tankyrase-IN-2	PARP Wnt	Cancer
Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC₅₀s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model .

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK	Metabolic Disease
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))

HY-147886

PARP1-IN-11 1 Publications Verification	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent PARP1 inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-152197

Tankyrase-IN-3	PARP	Cancer
Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer .

HY-147316A

TP-5801 TFA	STAT TNK1	Cancer
TP-5801 TFA is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity .

HY-12577

TNKS1/2-IN-1	PARP	Cancer
TNKS1/2-IN-1 (Example 4) is a *TNKS1* and *TNKS2* inhibitor, with pIC₅₀ values of 8.2 or 7.3 against *TNKS1, and 7.1 or 7.7 against TNKS2. TNKS1/2-IN-1 inhibits the enzymatic activities of TNKS1* and *TNKS2. TNKS*1/2-IN-1 is applicable for cancer research .

HY-146336

*PARP1/2/TNKS1/2-IN-1*	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, *TNKS1* and *TNKS2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-23338

TNKS-2-IN-1	PARP	Others
TNKS-2-IN-1 (Compound 13g) is a *TNKS-2* inhibitor. TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC₅₀s of 259 nM and 1100 nM .

HY-15147R

XAV-939 (Standard)	β-catenin PARP	Cancer
XAV-939 (Standard) is the analytical standard of XAV-939. This product is intended for research and analytical applications. XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .

HY-143338

ART-IN-1	PARP	Cancer
ART-IN-1 (compound 7) is a selective PARP inhibitor with IC₅₀s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .

HY-12602

TNKS-IN-4	PARP	Cancer
TNKS-IN-4 (compound 49) is an orally active tankyrase (TNKS) inhibitor with IC₅₀ values of 0.1 nM and 7.6nM for *TNKS1* and *TNKS2, respectively. TNKS*-IN-4 can be used for study of APC-mutant colorectal cancer .

HY-13990G

NVP-TNKS656 TNKS656	PPAR Apoptosis	Cancer
NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active *TNKS2* inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

HY-156332

TNKS-2-IN-2	PARP	Cancer
TNKS-2-IN-2 is a potent and selective inhibitor of *TNKS2* with an IC₅₀ of 22 nM .

HY-173480

TNKS-IN-3	PARP	Cancer
TNKS-IN-3 (Compound 6) is a *TNKS2* inhibitor (K_i: 8.5 nM). TNKS-IN-3 has good activity (IC₅₀: 71 nM) and can effectively inhibit the WNT/β-catenin signaling pathway. TNKS-IN-3 can be used in the research of diseases such as cancer and fibrosis .

HY-E70868

TNK1 Recombinant Human Active Protein Kinase	TNK1	Cancer
Thirty-eight-negative kinase-1 (TNK1) is a member of the ACK family of NRTKs, which includes only two human kinases, TNK1 and TNK2 (also called ACK1). TNK1 Recombinant Human Active Protein Kinase is a recombinant TNK1 protein that can be used to study TNK1-related functions .

HY-121719

TIQ-A	PARP	Cardiovascular Disease Cancer
TIQ-A is a potent *TNKS* (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for *TNKS2*. TIQ-A is a potential anti-ischemic agent .

HY-108516

TC-E 5001	Wnt PARP	Cancer
TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with K_ds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC₅₀s of 0.709 μM and 0.215 μM, respectively .

HY-100847

AZ0108	PARP	Cancer
AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC₅₀s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC₅₀ of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI₅₀ of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models .

HY-W294889

OUL245	PARP	Cancer
OUL245 is a 7-Hydroxy derivative, and a selectively PARP2 inhibitor (IC₅₀=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC₅₀s of 2.9-8.8 μM .

HY-12601

TNKS 22 TNKS-IN-22	PARP	Cancer
TNKS 22 (compound 22) is an orally active and selective tankyrase inhibitor. TNKS 22 inhibits *TNKS1* and *TNKS2* with IC₅₀s of 0.1 and 4.1 nM, respectively .

HY-15800

CZC-25146 hydrochloride	TNK1 LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases .

HY-172747

TNKS-2-IN-3	PARP	Cancer
TNKS-2-IN-3 (Compound 5) is a selective competitive tankyrase 2 (TNKS2) inhibitor with an IC₅₀ value of 0.3 nM, showing over 20-fold selectivity over TNKS1 and more than 100-fold selectivity over PARP1/2. TNKS-2-IN-3 stabilizes axin and suppresses the Wnt/β-catenin pathway by inhibiting TNKS2-mediated ADP-ribosylation, exhibiting antiproliferative activity in colorectal cancer cells. TNKS-2-IN-3 is proming for rasearch of solid tumors with aberrant Wnt pathway activation, such as colorectal cancer .

HY-153259

TNKS1/2-IN-2	TNK1 PARP	Cancer
TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC₅₀ values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC₅₀ values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer .

HY-117700

TNKS-IN-2	Wnt PARP	Cancer
TNKS-IN-2 (compound 40) is a potent and selective tankyrase (TNKS) inhibitor with pIC₅₀ values of 8.1, 7.0 for TANKS and Wnt, respectively .

HY-RS14840

Tnks Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks Mouse Pre-designed siRNA Set A Tnks Mouse Pre-designed siRNA Set A

HY-RS14841

Tnks Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks Rat Pre-designed siRNA Set A Tnks Rat Pre-designed siRNA Set A

HY-RS14839

TNKS Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS Human Pre-designed siRNA Set A TNKS Human Pre-designed siRNA Set A

HY-RS14844

Tnks2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnks2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnks2 Mouse Pre-designed siRNA Set A Tnks2 Mouse Pre-designed siRNA Set A

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701631

	TNKS1 Protein, Human (His) TNKS; Poly [ADP-ribose] polymerase tankyrase-1; ADP-ribosyltransferase diphtheria toxin-like 5; ARTD5; Poly [ADP-ribose] polymerase 5A; Protein poly-ADP-ribosyltransferase tankyrase-1; TNKS-1; TRF1-interacting ankyrin-related ADP-ribose polymerase; Tankyrase I; Tankyrase-1; TANK1	Human	E. coli
	The TNKS1 protein is a polyADP-ribosyltransferase that is integral to multiple cellular processes, including the Wnt signaling pathway, telomere length regulation, and vesicle trafficking. In Wnt signaling, TNKS1 activates this pathway by poly-ADP-ribosylating AXIN1 and AXIN2, promoting their degradation. TNKS1 Protein, Human (His) is the recombinant human-derived TNKS1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P701632

	TNKS1 Protein, Human TNKS; Poly [ADP-ribose] polymerase tankyrase-1; ADP-ribosyltransferase diphtheria toxin-like 5; ARTD5; Poly [ADP-ribose] polymerase 5A; Protein poly-ADP-ribosyltransferase tankyrase-1; TNKS-1; TRF1-interacting ankyrin-related ADP-ribose polymerase; Tankyrase I; Tankyrase-1; TANK1	Human	E. coli
	The TNKS1 protein is a polyADP-ribosyltransferase that is integral to multiple cellular processes, including the Wnt signaling pathway, telomere length regulation, and vesicle trafficking. In Wnt signaling, TNKS1 activates this pathway by poly-ADP-ribosylating AXIN1 and AXIN2, promoting their degradation. TNKS1 Protein, Human is the recombinant human-derived TNKS1 protein, expressed by E. coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87112

	TNKS1 Antibody (YA6805) ADP-ribosyltransferase diphtheria toxin-like 5 antibody; OTTHUMP00000115550 antibody; OTTHUMP00000224675 antibody; PARP 5a antibody; PARP5A antibody; PARPL antibody; pART5 antibody; Poly [ADP-ribose] polymerase 5A antibody; TANK 1 antibody; TANK1 antibody; ADP-ribosyltransferase diphtheria toxin-like 5 antibody; OTTHUMP00000115550 antibody; OTTHUMP00000224675 antibody; PARP 5a antibody; PARP5A antibody; PARPL antibody; pART5 antibody; Poly [ADP-ribose] polymerase 5A antibody; TANK 1 antibody; TANK1 antibody; Tankyrase 1 antibody; Tankyrase I antibody; Tankyrase TRF1 interacting ankyrin related ADP ribose polymerase antibody; Tankyrase-1 antibody; Tankyrase1 antibody; TankyraseI antibody; TIN 1 antibody; TIN1 antibody; TINF 1 antibody; TINF1 antibody; TNKS 1 antibody; TNKS antibody; TNKS-1 antibody; TNKS1 antibody; TNKS1_HUMAN antibody; TRF1 interacting ankyrin related ADP ribose polymerase antibody; TRF1-interacting ankyrin-related ADP-ribose polymerase antibody;	WB	Human, Mouse, Rat
	TNKS1 Antibody (YA6805) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TNKS1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13990G

NVP-TNKS656 TNKS656	PPAR Apoptosis	Cancer
NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active *TNKS2* inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: